5-(4-Fluorophenyl)-2-(1-Methylethyl)-N,4-Diphenyl-1-[2-[(2R,4R)-Tetrahydro-4-Hydroxy-6-Oxo-2H-Pyran-2-Yl]Ethyl]-1H-Pyrrole-3-Carboxamide

What governs lactone-to-API conversion consistency when scaling from pilot to commercial batch sizes?

The critical process parameter most frequently implicated in batch-to-batch polymorphic drift during scale-up is the rate of anti-solvent addition relative to the instantaneous supersaturation ratio of the nascent calcium salt. On a 500 L pilot vessel, linear water addition at 2.5 L/min reproducibly yields amorphous material with a specific surface area of 8–12 m²/g (BET, ASTM C1274-14), yet when geometrically scaled to a 4,000 L crystallizer, the identical linear rate creates local zones of high supersaturation that nucleate crystalline Form I domains detectable by XRPD at ≥0.3% after storage at 40 °C/75% RH for 14 days. Site-level corrective actions documented in FDA ANDA 076477-type submissions have shifted to a ramped anti-solvent protocol: an initial stage at 0.8 L per min per 1,000 L batch volume until the onset of turbidity, followed by a deceleration curve tuned to maintain a constant relative supersaturation of 1.08–1.12 until the batch is fully desolvated. The formulation addition ratio is anchored to the lactone input — 1.0 equivalent — with the calcium hydroxide charge adjusted to 0.535 ± 0.005 eq based on the saponification value of the incoming lactone lot. Compliance with EU GMP Part II, Chapter 8.0 handling of blending of multiple crystallizer drops is mandatory when aggregating sub-lots for a single batch. Downstream processing from this point follows a wet milling step using a 0.4 mm screen-equipped rotor-stator mill before vacuum drying, and the spray-dried calcium salt produced serves as the drug substance for film-coated tablets in 10 mg, 20 mg, 40 mg, and 80 mg dosage strengths.

When the isolated lactone is utilized as pharmacopoeial reference standard for impurity F in atorvastatin calcium drug substance and drug product release testing, the handling paradigm shifts from bulk API chemical processing to trace-level analytical weighing and solution stability management. The Ph. Eur. 10.8 monograph for Atorvastatin Calcium Trihydrate designates this lactone as Impurity F with an acceptance criterion of ≤0.15% in the drug substance, while USP Atorvastatin Calcium monograph specifies ≤0.2% for the lactone impurity by HPLC procedure 2. To prepare a stock solution, a quantity equivalent to 25.0 mg of the lactone standard is weighed on a microbalance with 0.01 mg readability and dissolved in 50.0 mL of diluent composed of acetonitrile:water 1:1 (v/v) adjusted to pH 3.0 with phosphoric acid; this stock is further diluted to a working concentration of 0.5 µg/mL for system suitability injections. The downstream HPLC method employs a 150 mm × 4.6 mm, 3 µm C18 column maintained at 30 °C with gradient elution of acetonitrile and ammonium formate buffer at pH 4.0, monitoring UV absorbance at 244 nm. Throughout the analytical sequence, the standard solution must be stored at 2–8 °C and used within 48 hours due to lactone ring instability in aqueous media; confirmation of solution integrity via peak purity analysis is integrated into every sequence. The terminal application output is a certified impurity reference standard batch issued with a comprehensive certificate of analysis citing traceability to WHO International Chemical Reference Substances or a national metrology institute.

Lactone ring-opening kinetics in the presence of non-stoichiometric calcium hydroxide and its impact on the diol acid impurity profile

Off-target hydrolysis pathways become kinetically competitive when the localized pH in the reaction boundary layer exceeds 10.2. In a standard semi-batch configuration with solid calcium hydroxide suspended in aqueous acetone, the dissolution rate of the base becomes rate-limiting below agitation power numbers of 1.3 × 10⁶, corresponding to tip speeds under 2.8 m/s in a 2,000 L vessel with a 1.2 m impeller. Under these conditions, the lactone (1.0 eq) encounters equivalent calcium at a time-averaged molar ratio of only 0.3–0.4, prolonging exposure of the β-hydroxy lactone intermediate to alkaline conditions and raising the diol acid impurity (Impurity D, CAS 887324-02-7) from a baseline 0.08% to 0.35% over a 2-hour addition window. Processing engineers monitoring real-time pH at the probe positioned 15 cm off the impeller tip have correlated diol acid climb with any pH excursion above 10.5 lasting longer than 45 seconds. Compliance with the ICH Q9 risk management framework therefore prescribes design space verification runs bracketing the agitation-to-addition rate ratio at 0.8× and 1.2× the proposed commercial set points. Downstream, the hydrolyzed crude calcium salt mixture is quenched by addition of acetic acid to pH 7.8–8.2 before polishing filtration through a 0.2 µm cartridge, followed by crystallization as described. The terminal product remains atorvastatin calcium (amorphous) with stringent individual impurity limits per ICH Q3A.

Direct compression grade atorvastatin calcium derived from this lactone intermediate requires upstream engineering of particle morphology during the final crystallization cascade, because post-crystallization dry milling alone introduces amorphous surface disorder that elevates the hygroscopicity and accelerates lactone re-formation during storage. In a production line validated against FDA SUPAC-IR guidance, the calcium salt slurry exiting the precipitation vessel at ~12% (w/w) solids is fed directly to a Niro P6.3 spray dryer with inlet temperature 165 ± 5 °C and outlet temperature 85 ± 3 °C, atomized via a two-fluid nozzle at 2.0 bar air pressure. The resulting powder exhibits a laser diffraction D[v,0.9] of ≤45 µm and a bulk density of 0.38–0.48 g/mL, which eliminates the need for roller compaction and allows direct blending with microcrystalline cellulose (Avicel® PH-102), croscarmellose sodium, and magnesium stearate in a 1,500 L tumble blender. The formulation addition ratio sets the drug substance at 10.34% (w/w) for a 10 mg tablet, corresponding to 10 mg atorvastatin per 96.7 mg core tablet weight. The finished dosage form is a round, white film-coated tablet with 8 mm diameter, released under USP <2040> dietary supplement verification where applicable but strictly to FDA 21 CFR 314.70 for post-approval changes in drug product composition. A critical terminal product limitation is the re-formation of the lactone impurity at 40 °C/75% RH open-dish storage: the lactone level climbs from <0.05% at release to 0.18% by 12 months when packaged in PVC/PVDC/Alu blisters, requiring a desiccant-loaded HDPE bottle pack configuration for climate zones III and IV.

Supply of this pyrrole carboxamide lactone to contract development and manufacturing organizations (CDMOs) engaged in late-stage clinical to commercial atorvastatin programs imposes cold-chain integrity and nitrogen-blanketed packaging standards exceeding those typical for simple pharmaceutical intermediates. Since residual oxygen levels above 500 ppm in the headspace of the secondary foil laminate bag have been correlated with a 0.02% per month increase in the diol acid degradation product during shipment at 2–8 °C, logistics protocols mandate triple-bagging with a PET/Al/LLDPE outer barrier film and an oxygen absorber sachet inserted between the inner and middle layers. Isotainer loading for ocean freight is qualified at 2–8 °C with a temperature excursion allowance of ≤15 °C for a cumulative duration not exceeding 6 hours per shipping lane, verified by EN 12830:2018-compliant data loggers placed at the four corners of each container. At the CDMO receiving dock, the material is incorporated into the calcium salt synthesis campaign operating under the harmonized quality agreement: a typical batch charges 112 kg of lactone (after 99.5 %(a/a) assay confirmation) to yield approximately 100 kg of atorvastatin calcium, with the lactone input amount reported in the Drug Master File open part as 1.05 kg per kg of final API. The downstream process replicates the validated hydrolysis–precipitation–spray drying sequence, and the resulting calcium salt is released against a joint specification referencing ICH Q6A decision trees for polymorphism and particle size. The terminal product is the same atorvastatin calcium drug substance dossier filed in eCTD Module 3.2.S.2 for ANDA or MAA submission.